It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The concept of “one target, one drug, one disease” is not always true, as compounds with previously described therapeutic applications can be useful to treat other maladies. For example, acridine derivatives have several potential therapeutic applications. In this way, identifying new potential targets for available drugs is crucial for the rational management of diseases. Computational methodologies are interesting tools in this field, as they use rational and direct methods. Thus, this study focused on identifying other rational targets for acridine derivatives by employing inverse virtual screening (IVS). This analysis revealed that chitinase enzymes can be potential targets for these compounds. Subsequently, we coupled molecular docking consensus analysis to screen the best chitinase inhibitor among acridine derivatives. We observed that 3 compounds displayed potential enhanced activity as fungal chitinase inhibitors, showing that compound 5 is the most active molecule, with an IC50 of 0.6 ng/µL. In addition, this compound demonstrated a good interaction with the active site of chitinases from Aspergillus fumigatus and Trichoderma harzianum. Additionally, molecular dynamics and free energy demonstrated complex stability for compound 5. Therefore, this study recommends IVS as a powerful tool for drug development. The potential applications are highlighted as this is the first report of spiro-acridine derivatives acting as chitinase inhibitors that can be potentially used as antifungal and antibacterial candidates.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Silva e Souza, Eden 2
; Sbaraini, Nicolau 3
; Vainstein, Marilene Henning 3
; Gomes, Joilly Nilce Santana 4
; de Moura, Ricardo Olímpio 4
; Barbosa, Euzébio Guimarães 5
1 Federal University of Rio Grande do Norte, Post-Graduate Program in Bioinformatics, Bioinformatics Multidisciplinary Environment, Natal, Brazil (GRID:grid.411233.6) (ISNI:0000 0000 9687 399X)
2 University College Dublin, School of Biomolecular and Biomedical Science & BiOrbic-Bioeconomy Research Center, Dublin, Ireland (GRID:grid.7886.1) (ISNI:0000 0001 0768 2743)
3 Federal University of Rio Grande do Sul, Biotechnology Center, Postgraduate Program in Cellular and Molecular Biology, Porto Alegre, Brazil (GRID:grid.8532.c) (ISNI:0000 0001 2200 7498)
4 State University of Paraíba, Department of Biological Sciences, Campina Grande, Brazil (GRID:grid.412307.3) (ISNI:0000 0001 0167 6035)
5 Federal University of Rio Grande do Norte, Post-Graduate Program in Bioinformatics, Bioinformatics Multidisciplinary Environment, Natal, Brazil (GRID:grid.411233.6) (ISNI:0000 0000 9687 399X); Federal University of Rio Grande do Norte, Post-Graduate Program in Pharmaceutical Sciences, Faculty of Pharmacy, Natal, Brazil (GRID:grid.411233.6) (ISNI:0000 0000 9687 399X)




